Variant allele frequencies and nucleotide changes at baseline vs relapse
| Gene . | BMA, 15%-25% lymphoma June 2017 (before ibrutinib) . | Peripheral blood sorted B cells March 2018 (after ibrutinib) . |
|---|---|---|
| TP53 | ||
| Alteration | p.F113V | p.F113V |
| Nucleotide | c.337T>G | c.337T>G |
| VAF, % | 27.5 | 96.9 |
| BTK | ||
| Alteration | None | p.C481S |
| Nucleotide | c.1442G>C | |
| VAF, % | 76.5 | |
| PLCG2 | ||
| Alteration | None | p.R665W |
| Nucleotide | c.1993C>T | |
| VAF, % | 2.1 |
| Gene . | BMA, 15%-25% lymphoma June 2017 (before ibrutinib) . | Peripheral blood sorted B cells March 2018 (after ibrutinib) . |
|---|---|---|
| TP53 | ||
| Alteration | p.F113V | p.F113V |
| Nucleotide | c.337T>G | c.337T>G |
| VAF, % | 27.5 | 96.9 |
| BTK | ||
| Alteration | None | p.C481S |
| Nucleotide | c.1442G>C | |
| VAF, % | 76.5 | |
| PLCG2 | ||
| Alteration | None | p.R665W |
| Nucleotide | c.1993C>T | |
| VAF, % | 2.1 |
BMA, bone marrow aspirate; VAF, variant allele frequencies.